$13.58 4%
ARQT Stock Price vs. AI Score
Data gathered: May 28

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Arcutis Biotherapeutics (ARQT)

Analysis generated December 16, 2024. Powered by Chat GPT.

Arcutis Biotherapeutics is a leading biopharmaceutical company dedicated to developing novel treatments for dermatological conditions. With a strong focus on innovation and patient-centric care, the company aims to address unmet clinical needs in dermatology through its robust pipeline of drug candidates. Founded on scientific rigor and clinical expertise, Arcutis Biotherapeutics has been making strides in the therapeutic landscape, particularly in conditions like psoriasis and atopic dermatitis.

Read full AI stock Analysis

Stock Alerts - Arcutis Biotherapeutics (ARQT)

company logo Arcutis Biotherapeutics | May 24
Insider Alert: Heron Patrick J is continuing buying shares
company logo Arcutis Biotherapeutics | May 21
Insider Alert: Edwards Larry Todd is selling shares
company logo Arcutis Biotherapeutics | May 20
Insider Alert: Heron Patrick J is continuing buying shares
company logo Arcutis Biotherapeutics | May 14
Insider Alert: Heron Patrick J is buying shares

Download our app to get future alerts delivered in real-time.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.


Arcutis Biotherapeutics
Price $13.58
Target Price Sign up
Volume 1,310,000
Market Cap $1.67B
Year Range $8.31 - $17.29
Dividend Yield 0%
Analyst Rating 100% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '2566M8.8M57M-25M0-0.200
Q4 '2471M6.9M64M-11M-4.5M-0.090
Q3 '2445M5.5M39M-42M-33M-0.330
Q2 '2431M3.5M27M-52M-44M-0.420
Q1 '2450M3.3M46M-35M-31M-0.320

Insider Transactions View All

Heron Patrick J filed to buy 22,534 shares at $13.7.
May 23 '25
Edwards Larry Todd filed to sell 183,104 shares at $14.1.
May 20 '25
Heron Patrick J filed to buy 17,494 shares at $13.6.
May 19 '25
Heron Patrick J filed to buy 14,974 shares at $13.8.
May 15 '25
Heron Patrick J filed to buy 8,674 shares at $13.8.
May 15 '25

What is the Market Cap of Arcutis Biotherapeutics?

The Market Cap of Arcutis Biotherapeutics is $1.67B.

What is the current stock price of Arcutis Biotherapeutics?

Currently, the price of one share of Arcutis Biotherapeutics stock is $13.58.

How can I analyze the ARQT stock price chart for investment decisions?

The ARQT stock price chart above provides a comprehensive visual representation of Arcutis Biotherapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Arcutis Biotherapeutics shares. Our platform offers an up-to-date ARQT stock price chart, along with technical data analysis and alternative data insights.

Does ARQT offer dividends to its shareholders?

As of our latest update, Arcutis Biotherapeutics (ARQT) does not offer dividends to its shareholders. Investors interested in Arcutis Biotherapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Arcutis Biotherapeutics?

Some of the similar stocks of Arcutis Biotherapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2025 AltIndex. All rights reserved.

Chat with AltIndex AI

👋 Welcome to AltIndex AI Chat!

Ask about:
  • Stock performance
  • AI score insights
  • Trending investment opportunities
  • How to use AltIndex
Start typing below to begin.
Disclaimer: AI outputs may be incorrect. This is for informational purposes only and not a substitute for professional financial advice.